Key Highlights

● 10x Genomics jumped on Friday, trading at about $84.09 by mid-morning, with no company announcement explaining the move.

● The stock moved with a broad rally in biotech and life-science tools that lifted a major biotech ETF solidly higher.

● 10x Genomics makes instruments, chips and reagents for single-cell and spatial biology research used in academia and drug discovery.

● The Russell 2000 rose 12.85 points to 2,806.98, though small caps still finished a fifth straight losing week.

10x Genomics (NASDAQ:TXG) jumped on Friday, trading at about $84.09 by mid-morning. No company announcement explained the move. The stock instead moved with a broad rally in biotech and life-science tools that was one of the session's standout themes.

The biotech bid was strong enough to lift a major biotech exchange-traded fund solidly higher intraday, and it pulled along everything from Vaccine developers to companies that make research instruments. 10x Genomics was one of several genomics names to benefit.

What 10x Genomics does

10x Genomics makes instruments, chips and reagents that let scientists study biology at the level of individual cells and map where genes are active inside tissue. Its single-cell and spatial biology platforms are widely used in academic research, cancer biology, immunology and neuroscience, and increasingly in drug discovery.

Because its sales depend on research budgets at universities, government labs and drug companies, the stock tends to react to shifts in sentiment about funding for life-science research and the outlook for the biotech industry.

The vaccine report that lit the fuse

That sentiment got a lift on Friday from a media report that the National Institutes of Health plans a public-private campaign, starting in December, to fast-track cancer-vaccine research. According to the report, the effort would initially focus on pancreatic, liver and colorectal cancers and some childhood tumors.

A government-backed push into cancer research could also matter for tools companies, since research programs of that kind often use the sort of cell-level analysis 10x sells. That said, the plan as reported is still at an early stage, and details on funding and participants have not been published.

The biggest movers were vaccine makers. Moderna (NASDAQ:MRNA) jumped $28.00 to $225.00, its highest close since 2021, and Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) also rallied. Among tools and genomics names, Illumina (NASDAQ:ILMN) climbed, Twist Bioscience (NASDAQ:TWST) rose sharply and Ginkgo Bioworks (NYSE:DNA) gained. Health care was among the S&P 500's leading sectors on the day.

Market backdrop

Stocks rose broadly. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, just shy of Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. The Russell 2000 rose 12.85 points to 2,806.98, though small caps still finished a fifth straight losing week.

The macro environment remained tough for growth stocks. The 10-year Treasury Yield held near a 24-year high, and the Fed, which raised rates in September for the first time since 2023, has signaled more tightening. Fed Governor Christopher Waller said Thursday he anticipates additional hikes to bring Inflation back to the Fed's goal. Consumer sentiment fell to a five-month low of 46.3 in the University of Michigan's preliminary October survey.

"It's the kind of back-and-forth market we've been in where we have the Reversal of sentiment around Iran," Ross Mayfield, Investment strategy analyst at Baird, said.

NIH Plan Details and Signs of Research Spending Will Guide 10x Genomics Next

Monday, October 12 is Columbus Day, with stocks open and the Bond Market closed. September consumer prices are due Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Official details of the NIH-linked initiative ahead of its expected December start, and signs that research spending is picking up, are the next items for 10x Genomics investors.